Answers are grounded in this paper and cite their sources.
Demonstrates that an active metabolite of AMG 221 matches parent potency and improves pharmacokinetics in rodents, highlighting its potential utility in type 2 diabetes.
All eight of the major active metabolites of (S)-2-((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one (AMG 221, compound 1), an inhibitor of 11β-hydroxysteroid dehydrogenase type 1 that has entered the clinic for the treatment of type 2 diabetes, were synthetically prepared and confirmed by comparison with samples generated in liver microsomes. After further profiling, we determined that metabolite 2 was equipotent to 1 on human 11β-HSD1 and had lower in vivo clearance and higher bioavailability in rat and mouse. Compound 2 was advanced into a pharmacodynamic model in mouse where it inhibited adipose 11β-HSD1 activity.
No takes yet. Share an insight, caveat, or question.
Li et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: